Form 4: IGMS CEO Reports Merger-Related Share Conversion

IGM Biosciences, Inc. completed its merger with Concentra Biosciences, converting shares and RSUs into cash and contingent value rights.

Summary

• IGM Biosciences, Inc. (IGMS) completed its merger with Concentra Merger Sub V, Inc., a subsidiary of Concentra Biosciences, LLC, on August 14, 2025.
• As a result of the merger, IGM Biosciences, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Each outstanding share of IGM Biosciences Common Stock and each outstanding Restricted Stock Unit (RSU) was cancelled.
• Shareholders and RSU holders received $1.247 in cash per share/RSU.
• Additionally, shareholders and RSU holders received one contractual contingent value right (CVR) per share/RSU, subject to a Contingent Value Rights Agreement.
• Mary Beth Harler, CEO and Director, reported the conversion of her 323,680 shares (including RSUs) into the merger consideration, resulting in zero beneficial ownership post-transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shareholders lose direct equity, the merger provides immediate cash and potential future upside via CVRs, which is an expected outcome for a company undergoing acquisition. The CVR introduces uncertainty, preventing a higher score.

Positives

• The merger provides immediate cash consideration of $1.247 per share/RSU to shareholders and RSU holders.
• The inclusion of a Contingent Value Right (CVR) offers potential future upside based on specific milestones or events, providing additional value beyond the upfront cash.
• The transaction was executed pursuant to a Rule 10b5-1 plan, indicating a pre-planned and orderly transaction for the reporting person.

Negatives

• IGM Biosciences, Inc. is no longer an independent publicly traded entity, becoming a wholly-owned subsidiary, which means its common stock is no longer traded.
• Shareholders lose direct equity ownership and future participation in the company's growth beyond the CVR terms.
• The value of the CVR is contingent and uncertain, dependent on future events and potentially subject to specific performance criteria that may not be met.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events, which may not materialize, potentially resulting in no additional value for shareholders.
• Shareholders no longer have direct exposure to the operational risks or potential upside of IGM Biosciences as an independent entity.

Future Outlook

The filing indicates the completion of a merger, resulting in IGM Biosciences becoming a wholly-owned subsidiary. The future outlook for former public shareholders is tied to the contingent value rights, which will pay out based on specific, undisclosed future events.

Industry Context

This merger represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller, often clinical-stage companies are acquired by larger entities. Such acquisitions are common strategies for larger companies to expand their pipeline or technology portfolio, while providing an exit for investors in the acquired company. The use of CVRs is a common mechanism in biotech mergers to bridge valuation gaps, especially for assets with uncertain future milestones.

Comparison to Industry Standards

• The specific terms of the merger ($1.247 cash plus CVR) would need to be compared against recent biotech acquisitions of companies at a similar stage of development or with comparable pipeline assets.
• Without specific details on the CVR milestones or the company's pipeline, a direct comparison to specific companies is not possible.
• The structure of cash plus CVR is a standard approach in biotech M&A, seen in deals such as Bristol Myers Squibb's acquisition of MyoKardia (which included CVRs for certain milestones) or Merck's acquisition of Acceleron Pharma.
• The specific value of $1.247 cash per share is relatively low, suggesting either a company in early-stage development, a challenging market, or that the primary value is expected to come from the CVR.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Former public shareholders received cash and CVRs, losing direct equity ownership in IGM Biosciences.
• Employees: While not explicitly stated, employees of IGM Biosciences are now part of Concentra Biosciences, LLC's corporate structure.
• Management: The former CEO, Mary Beth Harler, is no longer subject to Section 16 reporting requirements for IGM Biosciences, indicating a change in her role relative to the public entity.

Next Steps

• Shareholders and RSU holders will receive the cash consideration and CVRs as per the merger agreement.
• The CVRs will be subject to the terms and conditions of the Contingent Value Rights Agreement, implying potential future payments if specific milestones are met.

Key Dates

Recommendation

The company has been acquired, and its shares are no longer publicly traded. For existing shareholders, the transaction is complete, and they have received the merger consideration. For potential investors, there is no stock to buy or sell. The 'hold' recommendation applies to former shareholders who now hold CVRs, as they await potential future payments.

Keywords

IGM Biosciences, IGMS, Merger, Acquisition, Contingent Value Right, CVR, SEC Form 4, Insider Transaction, Biotechnology, Pharmaceuticals, Corporate Action